GL-N01

GL-N01 is an allogeneic natural killer (NK) cell therapy candidate currently in preclinical development by GILongevity, a subsidiary of GI Innovation. The therapy is specifically designed for immune restoration, targeting the reversal or mitigation of immune senescence—the gradual deterioration of the immune system associated with aging. By introducing healthy, functional NK cells, GL-N01 aims to replenish the body's innate immune population, thereby enhancing immune surveillance and the ability to eliminate stressed or dysfunctional cells. This approach is part of a broader pipeline focused on longevity and maintaining a robust immune environment to prevent age-related pathologies.